ArticleAmerican journal of translational research2026
Repeated low-intensity red light combined with defocus-incorporated multiple segments (DIMS) spectacles for controlling myopia progression in children.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and safety of repeated low-intensity red light (RLRL) therapy combined with defocus incorporated multiple segments (DIMS) spectacles for controlling myopia progression in children.
methodsIn this retrospective cohort study, medical records of 100 children with persistent myopia progression despite DIMS spectacle wear were reviewed. Patients were divided into two groups based on their treatment history: a DIMS-only control group (n=50) and an RLRL+DIMS combination group (n=50). Axial length (AL), spherical equivalent refraction (SER), uncorrected visual acuity (UCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFChT), corneal curvature (CC), fundus autofluorescence, adverse events were assessed at baseline and 1, 3, 6, 9 and 12 months.
resultsOf the 100 enrolled children, 92 completed the 12-month follow-up. Baseline characteristics were comparable between groups (all P>0.05). At 12 months, the combination group showed significantly less axial elongation than the control group (mean change: 0.060±0.237 mm vs. 0.386±0.183 mm, P<0.001), with 37.8% of children showing axial shortening. SER progression was also significantly slower in the combination group (change: +0.038±0.435 D vs. -0.720±0.295 D; P<0.001). SFChT increased significantly in the combination group (+13.2±27.4 μm) but decreased in controls (-3.3±12.4 μm, P<0.001). No significant changes in CRT or CC were observed. Transient glare occurred in nine children; one child withdrew due to an 8-minute afterimage. No abnormal fundus autofluorescence was detected.
conclusionRLRL combined with DIMS spectacles effectively increased choroidal thickness, delayed axial elongation, and slowed SER progression in myopic children over 12 months, with a favorable short-term safety profile. Longer-term studies are warranted to confirm sustained efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.